Sepsis, a life-threatening condition characterized by an overwhelming immune response to infection, often results in multi-organ failure and high mortality. While the elderly display increased vulnerability, younger populations may survive through yet poorly understood mechanisms of disease tolerance. The latest research conducted by Sanchez and colleagues delves deeply into the cardiac molecular adaptations underlying survival in young hosts confronted with sepsis, highlighting age-specific genetic regulation that differentiates survivors from those who succumb.

Central to this study is the transcription factor FoxO1, known for its roles in metabolism, oxidative stress responses, and muscle homeostasis. By profiling cardiac gene expression in young mice exposed to a lethal dose of polymicrobial sepsis (LD_50), the team identified a distinct set of FoxO1 target genes categorized into four classes based on differential expression patterns correlating with survival or fatality. Notably, two muscle-specific E3 ubiquitin ligases—Trim63 (MuRF1) and Fbxo32 (Atrogin1)—emerged within Class 2 atrogenes, known for their involvement in muscle remodeling.

Data revealed that in young survivors of sepsis, cardiac expression levels of Trim63 and Fbxo32 are significantly upregulated compared to both age-matched uninfected controls and non-surviving infected counterparts. Intriguingly, this dynamic was absent in aged mice, where no correlation between sepsis outcome and cardiac expression of these genes was detected. These results underscore a critical age-related differential regulation of FoxO1 targets in the heart during severe infection.

To unravel whether FoxO1 directly influences the induction of these atrogenes, the researchers administered a specific FoxO1 inhibitor to young infected mice. This intervention effectively prevented the upregulation of Trim63 and Fbxo32 in cardiac tissue, confirming FoxO1’s required role in modulating their expression during sepsis. These mechanistic insights cement FoxO1 as a key regulatory node orchestrating cardiac responses to systemic bacterial challenge.

The functional importance of Trim63, in particular, was evaluated by generating Trim63-deficient mice and subjecting them to low-dose polymicrobial sepsis. Remarkably, young mutants lacking Trim63 exhibited dramatically increased susceptibility to both morbidity and mortality compared to their wild-type littermates. This pronounced vulnerability was accompanied by profound cardiac remodeling marked by gross anatomical alterations, heart weight changes normalized to body weight, and evidence of tissue edema upon histological examination.

Further biochemical analyses revealed elevated serum markers indicative of cardiac injury, such as troponin I and brain natriuretic peptide (BNP), as well as markers for liver and kidney damage. The absence of Trim63 exacerbated systemic organ congestion, emphasizing its critical role beyond the heart. These findings establish Trim63 not only as a molecular marker but as an active mediator of disease tolerance, enabling cardiac and multiorgan integrity during septic insult.

Interestingly, although Trim63 is also expressed in skeletal muscle, its regulation in this tissue during sepsis did not correlate with survival outcomes in young mice, nor did FoxO1 inhibition affect skeletal muscle expression. Skeletal muscle mass was similarly unaffected by Trim63 deficiency during infection, indicating a cardiac-specific function for this gene in the context of sepsis. This tissue specificity highlights nuanced organ-level regulatory programs that govern infection responses.

The study’s implications extend far beyond murine models, as sepsis remains a formidable challenge in human medicine, particularly given the disparate outcomes observed across age groups. Understanding the molecular mechanisms by which young hearts mount protective remodeling could inspire novel therapeutic strategies aimed at enhancing cardiac resilience and systemic tolerance during overwhelming infections.

By delineating the FoxO1-Trim63 axis as a central component of sepsis-induced cardiac remodeling and disease tolerance, this research propels the field toward targeted interventions that leverage endogenous protective pathways. Future exploration into how these pathways intersect with immune system dynamics and metabolic shifts will be crucial to translate these findings into clinical advances.

Moreover, these insights prompt a reevaluation of age-related pathophysiology in sepsis, suggesting that loss of adaptive gene regulation contributes to poorer outcomes in the elderly. Therapeutics designed to activate or mimic FoxO1-induced Trim63 expression in cardiac tissue might provide protective benefits, reducing organ damage and improving survival rates.

In summary, Sanchez et al.’s study highlights a fascinating age-dependent gene regulatory mechanism that safeguards cardiac function during severe bacterial infection. By demonstrating the necessity of FoxO1-mediated induction of Trim63 for survival in young mice, this work identifies promising molecular targets for enhancing disease tolerance in sepsis and potentially other inflammatory conditions.

As sepsis continues to pose a major global health burden, breakthroughs illuminating fundamental disease resilience pathways are critical. This research not only advances our understanding of cardiac biology under infectious stress but also lays the groundwork for innovative approaches to combat sepsis-related morbidity and mortality in vulnerable populations across the lifespan.

Subject of Research: FoxO1-mediated regulation of cardiac atrogenes and disease tolerance in age-dependent responses to polymicrobial sepsis in mice.

Article Title: Disease tolerance and infection pathogenesis age-related tradeoffs in mice.

Article References:
Sanchez, K.K., McCarville, J.L., Stengel, S.J. et al. Disease tolerance and infection pathogenesis age-related tradeoffs in mice. Nature (2026). https://doi.org/10.1038/s41586-025-09923-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09923-x

Sepsis, a life-threatening condition caused by an overwhelming immune response to infection, commonly leads to multi-organ failure, with the heart being particularly vulnerable. The metabolic reprogramming and mitochondrial dysfunction observed in septic hearts frequently culminate in irreversible cardiac injury and death. However, until now, the molecular underpinnings that dictate cardiac tolerance—why some hearts better survive septic stress—remained elusive.

In this novel research, the scientists targeted mono-ADP-ribosylation, a lesser-explored mitochondrial post-translational modification whereby a single ADP-ribose unit is transferred to target proteins, influencing their function. This modification within cardiomyocyte mitochondria was hypothesized to act as a decisive modulator of the heart’s bioenergetic capacity under septic conditions. Employing sophisticated genetic and biochemical approaches, the team meticulously dissected the role of this modification in mitochondrial function and cardiac outcomes during sepsis.

The study demonstrated that mono-ADP-ribosylation serves as a molecular switch that configures the bioenergetic reserve of cardiac mitochondria. The bioenergetic reserve refers to the heart cells’ ability to increase ATP production above basal levels to meet acute energetic demands during stress. In septic mice, adequate mitochondrial mono-ADP-ribosylation maintained this reserve, enabling cardiomyocytes to sustain their energy-intensive functions despite systemic inflammation and oxidative stress.

Using male mice genetically engineered to lack the machinery for mitochondrial mono-ADP-ribosylation specifically in cardiomyocytes, the researchers observed a marked reduction in cardiac bioenergetic reserve capacity. These mice demonstrated heightened vulnerability to sepsis, developing more severe myocardial dysfunction and poorer survival rates compared to their wild-type counterparts. This compelling evidence highlighted the protective role of mitochondrial mono-ADP-ribosylation in preserving cardiac energy homeostasis during critical illness.

At the mechanistic level, the study elucidated how mono-ADP-ribosylation modulates key components of the electron transport chain and mitochondrial respiratory complexes, optimizing ATP synthesis efficiency. Altered ADP-ribosylation status influenced mitochondrial membrane potential and reactive oxygen species production, maintaining redox balance and preventing bioenergetic collapse. These insights underscore the importance of precise post-translational modification landscapes within mitochondrial proteomes for cardiac adaptability under stress.

Intriguingly, the research also found that this mitochondrial modification acts as a rapid and reversible signaling modality, allowing cardiomyocytes to dynamically tune their metabolic output in response to septic insults. Such agility ensures that energy demands are met without incurring excessive oxidative damage, a fine balance that underlies cardiac resilience. The potential reversibility of mono-ADP-ribosylation opens therapeutic avenues aiming to bolster mitochondrial function during sepsis through pharmacologic modulation.

Beyond its immediate impact on sepsis biology, the study advances a broader understanding of how mitochondrial post-translational modifications govern organ-specific bioenergetics. The heart, with its relentless energy demands and limited regenerative capacity, exemplifies an organ exquisitely sensitive to mitochondrial perturbations. This research suggests that restoring or enhancing mono-ADP-ribosylation might represent a universal strategy to reinforce mitochondrial performance in diverse cardiac pathologies featuring energetic deficits.

The findings also carry critical implications for personalized medicine. The observed sex specificity—experiments exclusively conducted in male mice—raises pertinent questions regarding sex-dependent differences in mitochondrial modification patterns and cardiac resilience. Future investigations elucidating the role of mono-ADP-ribosylation in female hearts and human tissues could uncover sex-specific therapeutic targets or biomarkers predictive of sepsis outcomes.

Furthermore, this study harnessed cutting-edge proteomics and high-resolution respirometry to quantify mitochondrial function with unprecedented detail. The integration of advanced molecular biology techniques with in vivo disease modeling provides a robust framework for dissecting complex bioenergetic phenomena in health and disease. This methodological synergy sets a new standard for the investigation of mitochondrial dynamics within intact organs under pathological stress.

Another remarkable aspect of the work lies in its translational potential. Sepsis remains a leading cause of mortality worldwide, and current treatments primarily address infection and systemic inflammation, offering little direct support for cardiac function. By identifying mitochondrial mono-ADP-ribosylation as a critical determinant of cardiac tolerance, this research lays the foundation for innovative therapeutic strategies designed to enhance mitochondrial resilience and improve patient survival.

Moreover, the study touches upon the broader role of ADP-ribosylation enzymes as targets for drug development. Small molecule modulators of mono-ADP-ribosyltransferases or hydrolases could be leveraged to fine-tune mitochondrial protein modification states in vivo. Such interventions might confer cardio-protection not only in sepsis but also in ischemic heart disease, heart failure, and other mitochondrial disorders.

Critically, the team’s data reveal a nuanced interplay between mitochondrial bioenergetics and cellular signaling pathways during sepsis. Alterations in mono-ADP-ribosylation influenced downstream processes including apoptosis, autophagy, and inflammatory cascades within cardiomyocytes. This multifaceted impact underscores the modification’s role as a central node integrating metabolic and stress-response networks in the heart.

Importantly, the research also highlights potential biomarkers detectable in cardiac tissue or circulation that correlate with mitochondrial mono-ADP-ribosylation levels and bioenergetic reserve status. Development of such biomarkers could enable early identification of patients at elevated risk of sepsis-induced cardiac dysfunction, improving triage and tailored therapeutic intervention.

The meticulous approach and comprehensive analysis presented in this study not only clarify the role of mitochondrial mono-ADP-ribosylation in cardiac sepsis but also open new horizons in the field of mitochondrial medicine. The ability to manipulate organelle-specific post-translational modifications offers exciting possibilities for enhancing organ function and resilience beyond traditional paradigms.

As sepsis incidence continues to rise globally, alongside increasing antimicrobial resistance and aging populations, innovative strategies that bolster host organ tolerance will be crucial to reducing mortality. This study’s revelations bring us one step closer to that goal, identifying mitochondrial mono-ADP-ribosylation as a vital determinant of cardiac tolerance and a promising target for therapeutic innovation.

In conclusion, this seminal work fundamentally shifts our perspective on cardiac adaptation in sepsis, establishing mitochondrial mono-ADP-ribosylation as a master regulator of bioenergetic reserve and organ survival. By decoding the mitochondrial “language” of post-translational modifications, the researchers have illuminated novel pathways that could be harnessed to mitigate the devastating impact of sepsis on the heart, potentially transforming clinical management and outcomes for this formidable condition.

Subject of Research:

Article Title:

Article References:
Chen, X., Yuan, T., Zheng, D. et al. Cardiomyocyte mitochondrial mono-ADP-ribosylation dictates cardiac tolerance to sepsis by configuring bioenergetic reserve in male mice. Nat Commun 16, 8119 (2025). https://doi.org/10.1038/s41467-025-62384-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-62384-8

Keywords: cardiomyocyte, mitochondrial mono-ADP-ribosylation, cardiac tolerance, sepsis, bioenergetic reserve, mitochondrial bioenergetics, post-translational modification, cardiac mitochondrial function, sepsis-induced cardiac dysfunction